Supplementary Figure 1-5 from Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019
figure
posted on 2023-03-31, 19:08 authored by Costanza Paoletti, Yufeng Li, Maria C. Muñiz, Kelley M. Kidwell, Kimberly Aung, Dafydd G. Thomas, Martha E. Brown, Vandana G. Abramson, William J. Irvin, Nancy U. Lin, Minetta C. Liu, Rita Nanda, Julie R. Nangia, Anna M. Storniolo, Tiffany A. Traina, Christos Vaklavas, Catherine H. Van Poznak, Antonio C. Wolff, Andres Forero-Torres, Daniel F. Hayes<p>Supplementary Figure 1-5. Supplementary Figure 1. Example of cluster image using the CellSearch<sup>®</sup> system. Supplementary Figure 2. REMARK diagram of the 19 patients who had elevated CTC (Group B/C) at baseline that were used to study "CTC-response". Supplementary Figure 3. PFS for TIG-treated patients versus the control group according to baseline CTC levels: CTC <5 (S2A) vs. {greater than or equal to}5 /7.5 ml WB (S2B) (note difference in time scale on y-axis). Supplementary Figure 4. Association of CTC-response level with RECIST response: ORR and CBR for group B and C as stated above. (Clinical response= either overall response rate (ORR) or clinical benefit response (CBR), as defined in method). Supplementary Figure 5. Association of CTC-apoptosis and response with RECIST response ORR and CBR. (Clinical response= either overall response rate (ORR) or clinical benefit response (CBR), as defined in method).</p>
